Until the next news. Lexg moves up in a hurry, so one just needs be patient. I like mesure Lexicon's progress through steps toward a goal making it easier to have patience. Coming up is another presentation which may or may not reveal much new, however, forward movement of any kind over this short time span is encouraging. There are two candidates that seem the most likely from the list to be the next to enter formal preclinical: LG267 for autoimmune disease with possible other indications such as leukemia and lymphoma and LG842 or 843, a biologic, partnered with DNA for metabolic syndrome (Dr. Sands seems particularly proud of this candidate).
At any time an out-licensing deal could be announced, a new partnership, or a government contract, but the next scheduled catalytic event may well occur at this quarter's earnings presentation. At that time, Lexicon will be very close to the probable first IND filing. I think a reasonable guess for the next IND would be four months from then. If Lexicon moves another candidate into formal preclinical soon we could see a nicely spaced succession form.
Patience is a requirement of investing, but Lexicon's growth and numerous developments through the year can enliven the wait for some personnal financial goal. It's going to happen step by step. While your out fishing (Ha Ha), gardening, at work, vacationing, etc, there are over 700 people working to make you richer. That ought to be some consolation before the next run up, though investors are rarely satisfied for long.
Some percentage of people seem to believe that a miracle announcement could be just around the corner. I suggest just looking at the real possibilites to know that Lexicon is moving forward in the framework of the time it really takes to bring drugs to market. The time can hardly be shortened, but the candidates brought forward by Lexicon seem exceptional and worth the wait.
The major investment in LEXG by Invus just a few days back is a sign some significant news may come relatively soon. They increased their position in AVII right before it took off from $3.50 to $8.50. They are quite savvy and must have a very good feeling here, as they took up their stake in LEXG to 3.3 million sh. from 1.8 million in the previous quarter.
"there are over 700 people working to make you richer" ain't it glorious?!!! not to mention the fact that they are working to make human life better, i.e., to cure people of certain debilitating conditions and diseases...
What happened to the platelet drug? One would assume that since it is a natural human protein, it could be fast tracked into trials since there would be fewer tox issues, at least not long term animal bioassays. They never talk about it any more. Has it gone the way of the kinase inhibitor cancer target?